ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14959376

Platinum –Based Anti Neoplastic Drugs and Hematotoxicity: Challenges in Cancer Treatmemt

[1]K . Gnanankitha; [2]A . Lahari; [3]V. Poojitha; [4]Paila. Bhanuji Rao; [5]Nimmala. Phani Satyavathi

Doctor of Pharmacy
Sri Venkateswara College of Pharmacy, Etcherla , Srikakulam , Andhra University , Vishakapatnam

Publication Date: 2025/03/03

Abstract: Platinum-based chemotherapy agents, such as cisplatin, carboplatin, and oxaliplatin, are essential in cancer treatment due to their ability to disrupt DNA replication and induce the death of tumor cells. However, their use is often linked with significant hematologic toxicities, particularly myelosuppression, which can lead to conditions like anemia, neutropenia, and thrombocytopenia. These side effects may require dose adjustments, treatment delays, and increase the likelihood of infections and bleeding complications.

This article delves into the mechanisms of hematotoxicity linked to platinum-based treatments, including bone marrow suppression, oxidative damage, and DNA crosslinking, all of which hinder normal blood cell production. It also reviews various management strategies, such as modifying drug doses, providing supportive treatments (e.g., G-CSF, erythropoietin-stimulating agents, and transfusions), and conducting regular hematologic monitoring. Ongoing research is focused on improving drug formulations, optimizing combination therapies, and developing protective strategies to reduce toxicity while preserving the drugs' therapeutic effects. A personalized approach to chemotherapy may reduce hematologic side effects and enhance patient outcomes in cancer care.

Keywords: *Platinum-Based Chemotherapy, Cisplatin, Carboplatin, Oxaliplatin, Hematologic Toxicity, Myelosuppression, Anemia, Neutropenia, Thrombocytopenia, DNA Crosslinking, Chemotherapy Side Effects, Cancer Treatment, Bone Marrow Suppression, Supportive Care In Oncology.*

How to Cite: K . Gnanankitha; A . Lahari; V. Poojitha; Paila . Bhanuji Rao; Nimmala. Phani Satyavathi (2025) Platinum –Based Anti Neoplastic Drugs and Hematotoxicity: Challenges in Cancer Treatmemt. *International Journal of Innovative Science and Research Technology*, 10(2), 1154-1158. https://doi.org/10.5281/zenodo.14959376

I. INTRODUCTION

Context Human neoplasms are frequently treated with platinum-based anticancer medications. The development of toxicity and resistance is the main barrier to the clinical usage of this class of medications. Therefore, it is crucial to comprehend these substances' chemical characteristics, transport and metabolic pathways, and mechanism of action. several studies have demonstrated that the harmful and therapeutic effects of platinum medicines on cells result from covalent adducts that develop between platinum complexes and DNA, RNA, and several proteins.

These procedures identify the molecular mechanisms underlying platinum medication toxicity and resistance. Both elevated repair of platinum-DNA adducts and elevated expression levels of certain transporters are thought to be the mostimportant mechanisms in the emergence of drug resistance. Predicting how patients will react to platinum medications is becoming more and more dependent on functional genomics. Genetic variations that impact these functions could be significant and serve as the foundation for a customized approach to cancer treatment.

The therapeutic potential of nonplatinum metal compounds with anticancer activity may potentially be influenced by similar processes. Conclusions The most widely used platinum-based chemotherapeutic drug that has been clinically shown to fight many cancers and sarcomas is cisplatin.

II. PLATINUM BASED ANTI NEOPLASTIC DRUGS

- *Commonly Used Drugs –Cis Platin , Carbo Platin , Oxi Platin*

- *Mechanism Action of Cisplatin:*

- Cisplatin is a chemotherapeutic substance that has characteristics similar to alkylation. A central platinum atom is cis-coordinated with two chlorine atoms and ammonia groups to form this inorganic, water-soluble

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14959376

combination (Rozencweig et al., 1977). A positively charged aquated complex is created when the chloride ligands dissolve in water and are progressively replaced by water molecules. Similar to alkylation processes, this activated form easily binds with nucleophilic sites on proteins, RNA, and DNA to form bifunctional covalent bonds.

- DNA structure is Especially with guanine and cytosine residues (DeVita et al., 1989). Interestingly, the only structure that shows anticancer action is cis-dichloro. Cisplatin has also been shown to have mutagenic [404] and immunosuppressive [401][402][403] qualities.changed and DNA replication is disrupted when intrastrand cross-links are formed,
- Cisplatin belongs to the as an alkylating agent that has nonspecific cell cycle action. Although the precise processes behind cisplatin resistance are yet unknown, intracellular glutathione or thiol-containing metallothionein protein levels are thought to play a role (DeVita et al., 1989). Interestingly, cisplatin does not show cross-resistance with Nitrosoreas or other alkylating drugs.

➢ *Mechanism Action of Carboplatin:*

- Carboplatin is a structural analogue of cisplatin, sharing similar anticancer properties but differing in its toxicity profile. The primary structural distinction between the two is that carboplatin contains a carboxycyclobutane group instead of the chloride ions found in cisplatin. Both drugs are considered cell cycle–nonspecific and exert their effects through a similar mechanism (Mong et al., 1980).

- The primary anticancer action of both carboplatin and cisplatin involves forming intra- and interstrand cross-links within the DNA, disrupting its structure and hindering replication. Carboplatin's dicarboxylate ligand is more stable than cisplatin's chloride ligands, which could influence its overall antitumor activity. Research has shown that the differences in cytotoxicity between these two drugs are related to how they interact with DNA over time, both in vitro and in vivo.

- Cisplatin undergoes hydrolysis, leading to unstable byproducts that quickly bind to plasma proteins and are primarily excreted via the kidneys. This process contributes to its nephrotoxic effects (Hrushesky, 1984). Carboplatin, on the other hand, is more soluble, remains chemically stable for a longer time, and binds to plasma proteins more slowly, which is thought to reduce its nephrotoxic potential (Wolpert-Defilippes, 1980). The differing kinetics of their interactions with DNA likely explain their distinct cytotoxic effects.

➢ *Mechanism Action of Oxaliplatin :*

- Oxaliplatin is activated in physiological conditions through a nonenzymatic process, where its oxalate ligand is displaced, resulting in the formation of active derivatives. This activation generates transient reactive species, including monoaquo and diaquo diaminocyclohexane (DACH) platinum, which can bind covalently to cellular macromolecules.

- The drug primarily causes interstrand and intrastrand DNA crosslinks at the N7 positions of guanine-guanine (GG), adenine-guanine (AG), and guanine-nucleotide-guanine (GNG) sites. These crosslinks interfere with DNA replication and transcription, leading to cytotoxic effects that are independent of the cell cycle phase.

- In vivo studies have shown that oxaliplatin is effective against colon carcinoma. When used in combination with 5-fluorouracil (5-FU), it significantly enhances antiproliferative activity compared to either agent alone, as demonstrated in various tumor models, including HT29 (colon cancer), GR (mammary cancer), and L1210 (leukemia).

III. HEMATOTOXICITY: AN ADVERSE EFFECTS OF PLATINUM DRUGS

❖ *Hematological Effects*

➢ *Hematological Effects of Cisplatin:*

Cisplatin, a chemotherapy agent, is frequently associated with significant hematological side effects, mainly due to its effects on bone marrow activity. The occurrence of these side effects differs based on the dosage and the individual characteristics of patients. Clinical data indicate the following broad patterns**:**

- *Myelosuppression:*

Thrombocytopenia (decreased platelet count): This affects approximately 10-30% of patients, with more intense cases more prevalent in those undergoing higher doses or combination therapies.

Anemia (lower red blood cell count): This is observed in about 10-30% of patients, resulting in fatigue and other related symptoms.

Leukopenia (decreased white blood cell count): This impacts around 10-40% of patients, with variations depending on the specific treatment plan.

Neutropenia (reduced neutrophil count): This is a frequent issue in 20-40% of patients, particularly when cisplatin is used alongside other chemotherapy medications.

- *Severe Hematological Issues:*

Severe thrombocytopenia: This occurs in 5-10% of patients, especially at elevated doses.

Severe neutropenia: This is found in 5-15% of patients, particularly when high doses or combination therapies are employed.

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14959376

Agranulocytosis (critically low neutrophil count): This is an uncommon but serious condition, impacting roughly 1-3% of patients, often associated with more aggressive or high-dose treatments.

The incidence of these complications is typically dose-dependent, with higher rates when cisplatin is administered in conjunction with other chemotherapy drugs. Continuous monitoring of blood counts is essential to modify treatment and reduce the likelihood of severe side effects.

➢ *Hematological Effects of Carboplatin:*

Carboplatin can cause various hematological side effects, including:

- Leukopenia (Decreased White Blood Cell Count): This condition increases the risk of infections due to a weakened immune system.
- Anemia (Decreased Red Blood Cell Count): Symptoms may include fatigue, pallor, and overall weakness as a result of reduced oxygen-carrying capacity.
- Thrombocytopenia (Decreased Platelet Count): Patients may experience an increased tendency to bruise or bleed due to impaired clotting ability.
- Neutropenia: A significant reduction in neutrophils can make individuals more susceptible to bacterial and fungal infections. In severe cases, febrile neutropenia may arise, requiring granulocyte colony-stimulating factor (G-CSF) therapy and preventive antibiotics.

Hematologic side effects occur with varying frequency: Anemia (21% to 90%), Leukopenia (26% to 71%), Neutropenia (16% to 67%), and Thrombocytopenia (35% to 62%).

➢ *Hematological Effects Of Oxaliplatin:*

Oxaliplatin can cause several hematological effects:

- Anemia: This is seen in 64% of patients treated with oxaliplatin alone, with the incidence rising to between 25% and 81% when used in combination with other therapies.
- Granulocytopenic Disorder: Severe cases (Grade 3 and 4) are reported in 39% to 45% of patients.
- Leukopenia: Found in 13% of patients on mono therapy, but the incidence increases to as high as 85% when oxaliplatin is combined with other treatments.
- Neutropenia: Affects 7% of those on mono therapy, while combination treatments result in higher rates of 71% to 81%.
- Thrombocytopenia: Occurs in 30% of patients receiving oxaliplatin alone, and this rate increases to 44% to 77% with combination therapy.

IV. MECHANISM OF HEMATOTOXICITY

➢ *Cisplatin :*

Cisplatin is known to induce myelosuppression, resulting in a reduction in the production of red blood cells, white blood cells, and platelets. This toxicity is dose-dependent and accumulates with prolonged exposure.

- Bone Marrow Damage: Cisplatin affects hematopoietic stem cells, leading to impaired production of blood cells.
- Oxidative Stress & DNA Injury: It causes DNA crosslinking and generates reactive oxygen species (ROS), triggering cellular damage and death.
- Neutropenia & Leukopenia: Cisplatin reduces the count of neutrophils and white blood cells, heightening the risk of infections; severe cases may necessitate granulocyte colony-stimulating factor (G-CSF) treatment.
- Anemia: The drug suppresses erythropoiesis, and its nephrotoxic effects worsen anemia by decreasing erythropoietin production.
- Thrombocytopenia: Low platelet levels increase the risk of bleeding and bruising.
- Hemolytic Uremic Syndrome (HUS): A rare but serious condition that involves hemolysis, thrombocytopenia, and kidney dysfunction.

Close monitoring of blood parameters and appropriate supportive care are crucial for managing these side effects.

➢ *Carboplatin:*

Red blood cells, white blood cells, and platelets are all affected by the myelo suppression caused by carboplatin; the most dose-limiting consequence is thrombocytopenia.

- Bone Marrow Suppression: Decreases blood cell production in a cumulative, dose-dependent way by harming hematopoietic stem cells.
- DNA Damage & Oxidative Stress: Produces platinum-DNA adducts, which interfere with replication and cause reactive oxygen species (ROS) to cause cell death.
- Neutropenia & Leukopenia: Reduces white blood cells, suppresses granulocyte precursors, and ddddraises the risk of infection; occasionally, G-CSF assistance is needed.
- Anemia: Decreases erythropoiesis and is exacerbated by renal toxicity, which hinders the generation of erythropoietin.
- Thrombocytopenia (Major Limiting Factor): A significant drop in platelets due to strong suppression of megakaryocytes raises the risk of bleeding and frequently calls for dose modifications.

➢ *Oxaliplatin :*

Oxaliplatin induces myelosuppression, resulting in a decrease in red blood cells, white blood cells, and platelets, with neutropenia being the most significant dose-limiting side effect.

- Bone Marrow Suppression: Oxaliplatin damages hematopoietic stem cells, causing a dose-dependent and cumulative reduction in blood cell production.
- DNA Damage & Oxidative Stress: The drug forms platinum-DNA adducts that hinder cell replication and promote apoptosis through the generation of reactive oxygen species (ROS).
- Neutropenia & Leukopenia: By impairing granulocyte precursor production, oxaliplatin increases the risk of infections, sometimes requiring granulocyte colony-stimulating factor (G-CSF) treatment.

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14959376

- Anemia: It suppresses erythropoiesis, leading to fatigue and exacerbating anemia with repeated treatment cycles.
- Thrombocytopenia: Oxaliplatin reduces megakaryocyte production, heightening the risk of bleeding, particularly when used alongside other therapies.

Consistent monitoring and supportive care are essential to manage these adverse effects effectively.

In order to manage these toxicities, supportive care and routine blood testing are essential.

V. EMERGING RESEARCH AND FUTURE DIRECTIONS

A clear understanding of the mechanisms behind hematotoxicity is essential for effective management. Approaches such as adjusting doses, providing supportive therapies like G-CSF and erythropoiesis-stimulating agents, administering blood transfusions, and conducting regular blood tests are crucial in alleviating these adverse effects. Ongoing research focuses on developing improved drug formulations, better combination therapies, and protective strategies to reduce toxicity while maintaining the effectiveness of treatment. Tailoring treatment plans to individual patients can also enhance safety and improve outcomes in cancer therapy.

Platinum-containing chemotherapy agents, such as cisplatin, carboplatin, and oxaliplatin, are crucial in cancer treatment. Nonetheless, their efficacy can often be undermined by hematotoxicity, which can harm blood cells, resulting in issues like anemia, neutropenia, and thrombocytopenia. Ongoing research is aimed at identifying methods to minimize these adverse effects and enhance the therapeutic effectiveness of these agents.

➢ *Key Advances in Platinum-Based Cancer Treatments:*

- Development of Innovative Platinum Compounds: Scientists are crafting new platinum compounds with modified ligands to improve their targeting capabilities and reduce toxicity. For instance, platinum-based heterometallic complexes that incorporate metals such as ruthenium or gold show potential in overcoming cisplatin resistance and decreasing detrimental side effects.
- Platinum(IV) Prodrugs: These prodrugs are inactive at first and only become toxic when activated within the tumor microenvironment. This precise approach seeks to enhance specificity towards cancer cells and lessen harmful impacts on other body systems, including hematotoxicity.
- Incorporation of Nanotechnology: The use of nanoparticles to encapsulate platinum drugs enhances the delivery of the medication to tumor locations, thus reducing exposure to healthy tissues and decreasing hematotoxicity. These nanoparticles also allow for controlled drug release, leading to improved treatment results.
- Combination Therapies: Investigators are looking into the pairing of platinum-based drugs with other treatments, such as photodynamic therapy (PDT). This integrative strategy can boost anticancer effectiveness while potentially reducing the necessary doses of each drug and their related toxicities.

➢ *Future Research Avenues*

Targeted Drug Delivery: Developing delivery systems that specifically target cancer cells can increase the concentration of medications at tumor sites, lessening exposure to healthy tissues and diminishing hematotoxicity.

Personalized Treatment: By employing genetic and molecular profiling of tumors, treatments with platinum-based therapies can be customized to meet individual patient needs, enhancing efficacy while reducing side effects such as hematotoxicity.

Biomarker Identification: Discovering biomarkers that indicate the likelihood of hematotoxicity will facilitate better patient monitoring and allow for more precise modifications to treatment plans, improving both safety and effectiveness.

VI. CONCLUSION

Platinum-based chemotherapy drugs, including cisplatin, carboplatin, and oxaliplatin, are vital in cancer treatment due to their ability to interfere with DNA replication and promote the death of cancer cells. However, their use is often linked to hematologic side effects, particularly myelosuppression, which can result in anemia, neutropenia, and thrombocytopenia. These issues may necessitate dose reductions, delays in treatment, and increase the risk of infections and bleeding.

REFERENCES

[1]. Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer, 7(8), 573–584.
[2]. Galanski, M., Jakupec, M. A., & Keppler, B. K. (2005). Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Current Medicinal Chemistry, 12(18), 2075–2094.
[3]. Pabla, N., & Dong, Z. (2008). Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney International, 73(9), 994–100.
[4]. Go, R. S., & Adjei, A. A. (1999). Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. Journal of Clinical Oncology, 17(1), 409–42
[5]. Ardalan, B., Flores, J., Shostak, Y., & Ardalan, B. (1990). Hematologic toxicity of carboplatin. Cancer Treatment Reviews, 17(1), 7–14.
[6]. Wang, D., & Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery, 4(4), 307–320

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14959376

[7]. Galsky, M. D., & Vogelzang, N. J. (2010). Myelosuppression in platinum-based chemotherapy: Strategies for prevention and management. Cancer Treatment Reviews, 36(1), 24–30
[8]. Oun, R., Moussa, Y. E., & Wheate, N. J. (2018). The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Transactions, 47(19), 6645–6653.
[9]. Markman, M. (2003). Toxicities of the platinum antineoplastic agents. Expert Opinion on Drug Safety, 2(6), 597–607.
[10]. Dilruba, S., & Kalayda, G. V. (2016). Platinum-based drugs: past, present and future. Cancer Chemotherapy and Pharmacology, 77(6), 1103–1124.
[11]. Wagstaff, A. J., Ward, A., Benfield, P., & Heel, R. C. (1989). Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs, 37(2), 162–198.
[12]. Theile, D., & Kos, M. (2016). Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs. Toxicology Letters, 242, 47–52.
[13]. Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., & Harrap, K. R. (1985). Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treatment Reviews, 12(Suppl A), 51–57.
[14]. Oun, R., & Wheate, N. J. (2018). Correction: The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Transactions, 47(23), 73
[15]. Beveridge, R. A., Miller, J. A., Kales, A. N., Binder, R. A., Robert, N. J., Harvey, J. H., Windsor, K., Gore, I., Cantrell, J., Thompson, K. A., Taylor, W. R., Barnes, H. M., & Schiff, S. A. (1998). A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Investigation, 16, 366–373.
[16]. Urbonas, V., Eidukaite, A., & Tamuliene, I. (2012). The diagnostic value of interleukin-6 and interleukin-8 for early prediction of bacteremia and sepsis in children with febrile neutropenia and cancer. Journal of Pediatric Hematology/Oncology, 34, 122–127.
[17]. Hao, J., Sun, L., Huang, H., Xiong, G., Liu, X., Qiu, L., Chen, G., Dong, B., Li, Y., Chen, W., Buechler, Y., Sun, J., Shen, C., & Luo, Q. (2004). Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys. Radiation Research, 162, 157–163
[18]. Azuaje, F. J., Zhang, L., Devaux, Y., & Wagner, D. R. (2011). Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs.
[19]. Rosenberg B, et al. (1965). Nature.
[20]. Dasari S, Tchounwou PB. (2014). Front Pharmacol.
[21]. Kelland L. (2007). Nat Rev Cancer.
[22]. Wang D, Lippard SJ. (2005). Nat Rev Drug Discov.
[23]. Stewart DJ. (2007). Cancer Chemother Pharmacol.
[24]. Einhorn LH. (2002). J Clin Oncol.
[25]. Marullo R, et al. (2013). J Cell Mol Med.
[26]. Deavall DG, et al. (2012). J Toxicol.
[27]. Rybak LP, et al. (2019). Antioxid Redox Signal.
[28]. Oun R, et al. (2018). Cancer Chemother Pharmacol.
[29]. Arany I, Safirstein RL. (2003). Kidney Int.
[30]. Ghosh S. (2019). J Hematol Oncol.
[31]. Crawford J, et al. (2004). J Clin Oncol.
[32]. Visvader JE, et al. (2011). Blood.
[33]. DeVita VT, et al. (2011). Cancer: Principles and Practice of Oncology.
[34]. Smith TJ, et al. (2015). J Clin Oncol.
[35]. Yousef MI, et al. (2009). Toxicology.
[36]. Crawford J, et al. (2006). Support Care Cancer.
[37]. Pabla N, Dong Z. (2008). Toxicol Sci.
[38]. Chovanec M, et al. (2017). Nat Rev Urol.